玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

首頁(yè)
訂購(gòu)/客服:400-666-5481

PF06650833

    
99.7%

PF06650833

源葉(MedMol)
S84042 一鍵復(fù)制產(chǎn)品信息
1817626-54-2
C18H20FN3O4
361.3675
6-Isoquinolinecarboxamide,1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-2-pyrrolidinyl)methoxy)-7-methoxy-
貨號(hào) 規(guī)格 價(jià)格 上海 北京 武漢 南京 購(gòu)買數(shù)量
S84042-5mg
99.7% ¥470.00 7 - - -
S84042-10mg
99.7% ¥810.00 5 - - -
S84042-50mg
99.7% ¥3500.00 3 - - -
產(chǎn)品介紹 參考文獻(xiàn)(1篇) 質(zhì)檢證書(shū)(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas

產(chǎn)品描述: Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas
靶點(diǎn): IRAK4:0.2 nM (IC50);IRAK
體外研究: The kinome selectivity profile of Zimlovisertib (Compound 40) is assessed in a panel of 278 kinases (Invitrogen) at 200 nM inhibitor concentration using the ATP Km for each kinase. Approximately 100% inhibition is observed for IRAK4. Lactam Zimlovisertib is assessed in a whole cell functional VEGF2R assay (PAE-KDR cell line). No activity is observed at concentrations up to and including 30 μM. In a voltage clamp assay, Zimlovisertib inhibits hERG current by 25% at 100 μM. The ability of Zimlovisertib to inhibit five major CYP450 enzymes is assessed using pooled human liver microsomes and probe substrates for the CYP450 enzymes. At a concentration of 3 μM of Zimlovisertib, less than 5% inhibition of CYPs 1A2, 2C8, 2C9, 2D6, and 3A4 is observed. Lactam Zimlovisertib is examined for time dependent inhibition effects on six major CYP450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2D6) using pooled human liver microsomes and probe substrates. At 100 μM of Zimlovisertib, no time dependent CYP inhibition is observed. The potential induction of CYP3A by Zimlovisertib is assessed using cryopreserved human hepatocytes and afforded a 4.4-fold increase in mRNA at 10 μM
體內(nèi)研究: Zimlovisertib (0.3-30 mg/kg; oral administration; for 2.5 hours; male Sprague-Dawley rats) treatment significantly inhibits LPS-induced TNF-α in a dose dependent manner. Mean exposures of Zimlovisertib in plasma are 2.1 nM, 7.7 nM, 19 nM and 150 nM free, respectively, at 2.5 hours after oral administration of Zimlovisertib at 0.3, 1, 3, and 30 mg/kg. The fraction unbound in rat plasma of Zimlovisertib is 0.3. Animal Model: Male Sprague-Dawley rats Dosage: 0.1 mg/kg, 1 mg/kg, 3 mg/kg, 30 mg/kg Administration: Oral administration; for 2.5 hours Result: Significantly inhibited LPS-induced TNF-α in a dose dependent manner.
參考文獻(xiàn): 1. Lee KL, et al. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13;60(13):5521-5542. 2. Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015). Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
溶解性: Soluble  in  DMSO
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 2.767 ml 13.836 ml 27.673 ml
5 mM 0.553 ml 2.767 ml 5.535 ml
10 mM 0.277 ml 1.384 ml 2.767 ml
50 mM 0.055 ml 0.277 ml 0.553 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

質(zhì)檢證書(shū)(COA)

如何獲取質(zhì)檢證書(shū)(COA)?
請(qǐng)輸入貨號(hào)和一個(gè)與之匹配的批號(hào)。
例如:
批號(hào):JS298415 貨號(hào):S20001-25g
在貨品標(biāo)簽上如何找到貨號(hào)和批號(hào)?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×
主站蜘蛛池模板: 沂源县| 始兴县| 西安市| 汶川县| 基隆市| 保靖县| 安吉县| 怀柔区| 怀仁县| 连云港市| 米易县| 夏津县| 汉源县| 益阳市| 四会市| 永胜县| 五寨县| 瑞昌市| 乌鲁木齐县| 怀远县| 视频| 大足县| 昌都县| 嫩江县| 炉霍县| 扬州市| 元朗区| 泸州市| 汉寿县| 康平县| 嘉荫县| 鄢陵县| 项城市| 嘉禾县| 苍南县| 太和县| 鹤山市| 新乡县| 开封县| 吉水县| 扎囊县|